Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

26 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Secondary hyperparathyroidism in chronic dialysis patients: results of the Italian FARO survey on treatment and mortality.
Brancaccio D, Cozzolino M, Cannella G, Messa P, Bonomini M, Cancarini G, Caruso MR, Cascone C, Costanzo AM, di Luzio Paparatti U, Mazzaferro S; FARO Study Group. Brancaccio D, et al. Among authors: costanzo am. Blood Purif. 2011;32(2):124-32. doi: 10.1159/000325454. Epub 2011 May 28. Blood Purif. 2011. PMID: 21625082 Clinical Trial.
VDRA therapy is associated with improved survival in dialysis patients with serum intact PTH ≤ 150 pg/mL: results of the Italian FARO Survey.
Cozzolino M, Brancaccio D, Cannella G, Messa P, Gesualdo L, Marangella M, LoDeserto C, Pozzato M, Rombolà G, Costanzo AM, di Luzio Paparatti U, Mazzaferro S; FARO Study Group. Cozzolino M, et al. Among authors: costanzo am. Nephrol Dial Transplant. 2012 Sep;27(9):3588-94. doi: 10.1093/ndt/gfs108. Epub 2012 Apr 20. Nephrol Dial Transplant. 2012. PMID: 22523119 Free article.
Achievement of NKF/K-DOQI recommended target values for bone and mineral metabolism in incident hemodialysis patients: results of the FARO-2 cohort.
Cozzolino M, Messa P, Brancaccio D, Cannella G, Bolasco P, Di Luca M, Costanzo AM, Paparatti Ud, Festa V, Gualberti G, Mazzaferro S; FARO Study Group. Cozzolino M, et al. Among authors: costanzo am. Blood Purif. 2014;38(1):37-45. doi: 10.1159/000365386. Epub 2014 Sep 27. Blood Purif. 2014. PMID: 25277167 Free article.
Evaluating targets and costs of treatment for secondary hyperparathyroidism in incident dialysis patients: the FARO-2 study.
Roggeri DP, Cozzolino M, Mazzaferro S, Brancaccio D, Paoletti E, Roggeri A, Costanzo AM, di Luzio Paparatti U, Festa V, Messa P. Roggeri DP, et al. Among authors: costanzo am. Int J Nephrol Renovasc Dis. 2014 Dec 16;8:1-6. doi: 10.2147/IJNRD.S72011. eCollection 2015. Int J Nephrol Renovasc Dis. 2014. PMID: 25565880 Free PMC article.
Pharmacological control of secondary hyperparathyroidism in hemodialysis subjects: a cost consequences analysis of data from the FARO study.
Roggeri DP, Mazzaferro S, Brancaccio D, Cannella G, Messa P, Di Luca M, Morosetti M, Costanzo AM, di Luzio Paparatti U, Cornago D, Cozzolino M; FARO Study Group. Roggeri DP, et al. Among authors: costanzo am. J Med Econ. 2012;15(6):1110-7. doi: 10.3111/13696998.2012.703632. Epub 2012 Jul 6. J Med Econ. 2012. PMID: 22702445 Free article.
Prognosis and determinants of serum PTH changes over time in 1-5 CKD stage patients followed in tertiary care.
Borrelli S, Chiodini P, De Nicola L, Minutolo R, Provenzano M, Garofalo C, Remuzzi G, Ronco C, Cozzolino MG, Manno C, Costanzo AM, Gualberti G, Conte G. Borrelli S, et al. Among authors: costanzo am. PLoS One. 2018 Aug 23;13(8):e0202417. doi: 10.1371/journal.pone.0202417. eCollection 2018. PLoS One. 2018. PMID: 30138402 Free PMC article. Clinical Trial.
26 results